Search

Displaying results 2631 - 2640 of 10000 in total
  1. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    in Pompe disease. … ,[L45275] and the EMA fully approved the drug on March 27, 2023.

  2. Drug

    Dorocubicel

    go.drugbank.com/drugs/DB19448
    Approved

    [L54106] Dorocubicel, as a component of Zemcelpro, was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation … following myeloablative conditioning in adult patients for whom a suitable donor is not available.

  3. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    FDA approved on May 19, 2009.

  4. Drug

    Hydroxocobalamin

    go.drugbank.com/drugs/DB00200
    ApprovedInvestigational

    It is also used in cyanide poisoning, Leber's optic atrophy, and toxic amblyopia. … Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency.

  5. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    Sotatercept is an activin signalling inhibitor. … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP pathway signalling observed in PAH.

  6. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    [L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.

  7. Drug

    Pinacidil

    go.drugbank.com/drugs/DB06762
    Approved

    The above processes result in reduced blood pressure. This drug has been discontinued by the FDA.

    Categories: Arteriolar Smooth Muscle, Agents Acting On
  8. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients.

  9. Drug

    Imipenem

    go.drugbank.com/drugs/DB01598
    ApprovedInvestigational

    [A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. … Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]

    Mixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUNSynonyms: N-formimidoylthienamycin, N-formimidoyl thienamycin
  10. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common … Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma.